The idiopathic inflammatory myopathies (IIM) encompass a heterogeneous group of rare disorders that present with acute, subacute, or chronic muscle weakness. Besides overlapping clinical manifestations, polymyositis, dermatomyositis and autoimmune necrotizing myopathy may be associated with cancer or collagen vascular disease, and respond generally well to immunosuppressive therapy. However, these 3 IIM are divergent from the histopathological and pathogenetic standpoints. On the other hand, inclusion body myositis (IBM), the most common IIM in the elderly, is clinically, histopathologically and pathogenetically distinct. IBM is also refractory to all currently available therapies. In this manuscript, we depict advances in our knowledge of the IIM, with emphasis on clinical presentation, associated conditions, laboratory features, electrophysiology, muscle histopathology, pathogenesis, and therapy
The idiopathic inflammatory myopathies (IIM) are a group of rare disorders that share many similarities. They present acutely, subacutely, or chronically with marked proximal and symmetric muscle weakness, except for associated distal and asymmetric weakness in inclusion body myositis (IBM). The IIM also share a variable degree of creatine kinase (CK) elevation and a non-specifically abnormal electromyogram demonstrating what is referred to as an irritative myopathy. The muscle pathology demonstrates inflammatory exudates of variable distribution within the muscle fascicle. Despite these similarities, the IIM are a heterogeneous group of muscle disorders from the clinical, histopathological, pathogenetic, and treatment-response standpoints (Dimachkie and Barohn, 2009) .
Other less common myositidis include granulomatous myositis, eosinophilic myositis, infectious myositis, the overlap syndrome, and non-specific myostis. Granulomatous myositis, with or without associated sarcoidosis, may clinically resemble polymyositis (PM), but tissue pathology usually shows giant cell granulomata. Sarcoidosis is also a common cause of focal pseudohypertrophic myositis of the calf or biceps muscle. Though extremely rare, eosinophilic myositis is associated with persistent eosinophilia for at least six months and lacks any parasitic infestation or allergic reaction. It presents like PM but carries a poor prognosis due to fatal cardiac complications. Infectious myositis is mainly associated with HIV or HTLV1. HIV myositis presents with painless proximal weakness, pathologic evidence of myositis and rarely nemaline rod bodies (Johnson et al., 2003) . Patients with non-specific myositis demonstrate a perimysial and perivascular inflammatory infiltrate, and 40% have associated connective tissue disease (van der Meulen et al., 2003) . The overlap syndrome (OS) refers to the association of PM, dermatomyositis (DM), or necrotizing myopathy (NM) with connective tissue disease such as scleroderma or systemic lupus erythematosus. In addition to elevated antinuclear antibodies (ANA), patients with OS may be weaker in the proximal arm musculature than the leg muscle mimicking the pattern seen in some of the muscular dystrophies.
In this review, we focus on DM, PM, and NM, and conclude with a discussion of sporadic inclusion body myositis (IBM) ( Table 1) . We also examine current and promising therapies of DM, PM and NM, as well as the essentially negative clinical trials in IBM.
Epidemiology
The IIM are rare sporadic disorders. The overall annual incidence of the IIM, using older diagnostic criteria, is approximately one in 100,000. Except for juvenile dermatomyositis, the IIM are diseases of the adult. They affect more women than men, except for IBM where the male-to-female ratio may be as high as 3/1. Interestingly, the ageadjusted prevalence of IBM in people over the age of 50 is 3.5/100,000, making it the most common IIM in this age group (Phillips et al., 2000) . In the Mayo Clinic series of 107 patients with pathologic features of PM or IBM, 64 had IBM pathology, and 16 had PM pathology with IBM clinical features (Chahin and Engel, 2008) . IBM is rare in AfricanAmericans. There is recent controversy around the frequency of PM. In a retrospective study from the Netherlands that originally excluded IBM, PM was reported to be less common than previously thought, accounting for as low as 2% of cases (van der Meulen et al., 2003) . However, a PM clinical phenotype was the most common cause of PM pathology in the Mayo Clinic case series (Chahin and Engel, 2008 
